The Group's principal activity is developing and commercializing novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. It has a product in clinical development Fampridine SR. Fampridine SR develops in human clinical trials for both MS and spinal cord injury. The Group is currently conducting a Phase 3 clinical trial of Fampridine SR in MS. Additionally, it is also developing multiple approaches to regeneration and repair of the spinal cord and brain.
Alacra Alerts:
Receive alerts on the latest reports on Acorda Therapeutics Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
